.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Dow
McKesson
Mallinckrodt
Teva
Daiichi Sankyo
McKinsey
Fish and Richardson
Baxter
Johnson and Johnson

Generated: July 22, 2017

DrugPatentWatch Database Preview

RESCRIPTOR Drug Profile

« Back to Dashboard

Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-two patent family members in twenty countries.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Two suppliers are listed for this compound. Additional details are available on the delavirdine mesylate profile page.

Summary for Tradename: RESCRIPTOR

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list57
Clinical Trials: see list7
Patent Applications: see list2,016
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RESCRIPTOR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 1997RXYesNo► Subscribe► Subscribe
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 1999RXYesYes6,177,101► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 19975,563,142► Subscribe
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 19995,563,142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: RESCRIPTOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,108,864Tablet formation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RESCRIPTOR

Country Document Number Estimated Expiration
Japan2002517430► Subscribe
Australia4213499► Subscribe
Austria349203► Subscribe
Canada2328703► Subscribe
European Patent Office1083885► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Deloitte
Julphar
Baxter
Accenture
US Department of Justice
Mallinckrodt
Cantor Fitzgerald
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot